Protecting Innovation to Empower Global Impact

Our intellectual property portfolio safeguards our delivery platforms, therapeutic modalities, and clinical programmes, enabling strategic collaborations and global patient reach.
Contact Our Business Development Team
View Partnering Portal
Property Strategy
Property Strategy Property Strategy
At Dawn Therapeutics, intellectual property (IP) is a core strategic asset. We build our IP portfolio to:
CNS
Cartilage
Muscle
Liver

Protect proprietary delivery technologies for CNS, cartilage, muscle, and liver targeting.

Secure therapeutic candidates across multiple rare and complex disease areas.

Enable exclusive commercial rights for our partners and licensees.

Strengthen market position with broad territorial coverage.

Property Strategy

Key Areas of Patent Protection

Our patent filings cover:

1. Tissue-Targeted Delivery Systems

–Engineered AAV capsids with enhanced CNS, cartilage, and muscle tropism.
–Ligand-functionalised LNPs for targeted mRNA delivery.

2.Therapeutic Modalities

– AAV vector genome designs and expression cassettes. – Optimised mRNA sequences for high protein yield and low immunogenicity. – RNAi and antisense oligonucleotide chemistries. – Gene editing constructs for precision correction

3.Manufacturing & CMC

–Scalable production methods for clinical-grade AAV and LNP-mRNA. –Purification and formulation processes optimised for stability and potency.

4. Therapeutic Programmes

–Composition of matter and method-of-use claims for selected CNS, lysosomal, and musculoskeletal disease indications.

Patent Coverage & Territories

Our portfolio includes filed and granted patents in:

North America

United States, Canada.

Europe

EU member states, UK, Switzerland, Norway.

Asia-Pacific

Japan, China, South Korea, Australia, Singapore.

Other Regions

Middle East, South America, Africa — filed strategically depending on market opportunity.

Innovation Pipeline Protection

  • Platform-Level Protection: Secures our ability to deploy the same delivery platform across multiple indications.
  • Indication-Specific Patents: Protects individual therapeutic programmes and disease applications.
  • Freedom-to-Operate (FTO) Analyses: Conducted regularly to avoid infringement risks.

Why Our IP Matters to Partners

  • Enables exclusive rights in defined markets.
  • Strengthens licensing potential with robust legal protection.
  • Enhances valuation for investment and acquisition opportunities.
  • Supports regulatory exclusivity alongside patent life.
Partner With Us

Representative Patents

(Publicly Disclosable Examples — fictional numbers for illustration)

  • WO2023/012345: Engineered AAV vectors for targeted CNS delivery.
  • US 11,234,567 B2: Ligand-modified LNP for cartilage-targeted mRNA delivery.
  • EP 3 456 789 A1: Methods for scalable production of high-purity AAV.
  • JP 2024-567890: Gene therapy for Hurler Syndrome (MPS I).

Confidentiality & Access

For details on unpublished patents or pending applications:

  • Access is restricted to partners under NDA.
  • Summaries are available upon request for due diligence purposes.
  • Patent portfolio updates are shared during partnership negotiations.
Partner With Us
Scroll to Top